Literature DB >> 4001731

Rubella--world impact.

F Assaad, K Ljungars-Esteves.   

Abstract

Worldwide, rubella is considered a public health problem because of the risk of infection to the fetus and of subsequent congenital defects. It is not a notifiable disease in most countries, and even where it is, it is underreported, and greater than 50% of infections are clinically inapparent. The impact of rubella is therefore gauged mainly through seroepidemiologic studies. Rubella appears to be endemic worldwide except in some remote areas or islands, where explosive outbreaks may occur. In general, a large proportion of a population is infected before puberty, but approximately 20% of adults may remain susceptible. Effective vaccines against congenital rubella exist, and many countries have already begun or are considering initiating large-scale immunization programs. In the developing world, where problems compete for priority in the mobilization of meager available resources, certain factors need to be considered before such programs are launched, including the ability to effectively deliver a program, the relationship between susceptibility and the age-fertility pattern, the incidence of congenital rubella, and the cost-effectiveness of intervention.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4001731     DOI: 10.1093/clinids/7.supplement_1.s29

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana.

Authors:  J E Lawn; S Reef; B Baffoe-Bonnie; S Adadevoh; E O Caul; G E Griffin
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Pregnant women in and around dhaka city: are their children at risk of developing congenital rubella syndrome?

Authors:  Hasan Imam; Mahmuda Yasmin; Chowdhury Rafiqul Ahsan; Jamalun Nessa
Journal:  Indian J Microbiol       Date:  2011-02-02       Impact factor: 2.461

3.  Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.

Authors:  L A Mitchell; M K Ho; J E Rogers; A J Tingle; R G Marusyk; J M Weber; P Duclos; M L Tepper; M Lacroix; M Zrein
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  Expression and characterization of virus-like particles containing rubella virus structural proteins.

Authors:  Z Qiu; D Ou; T C Hobman; S Gillam
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Identification of T-cell epitopes on E2 protein of rubella virus, as recognized by human T-cell lines and clones.

Authors:  D Ou; P Chong; Y Choi; P McVeigh; W A Jefferies; G Koloitis; A J Tingle; S Gillam
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Analysis of T- and B-cell epitopes of capsid protein of rubella virus by using synthetic peptides.

Authors:  D Ou; P Chong; B Tripet; S Gillam
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination.

Authors:  M Zrein; J H Joncas; L Pedneault; L Robillard; R J Dwyer; M Lacroix
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

8.  Rubella seroepidemiology in a non-immunized population of São Paulo State, Brazil.

Authors:  R S De Azevedo Neto; A S Silveira; D J Nokes; H M Yang; S D Passos; M R Cardoso; E Massad
Journal:  Epidemiol Infect       Date:  1994-08       Impact factor: 2.451

9.  The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme.

Authors:  L Matter; F Bally; D Germann; K Schopfer
Journal:  Eur J Epidemiol       Date:  1995-06       Impact factor: 8.082

10.  Sero-survey of rubella IgM antibodies among children in Jos, Nigeria.

Authors:  Surajudeen A Junaid; King J Akpan; Atanda O Olabode
Journal:  Virol J       Date:  2011-05-19       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.